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Pifithrin- (PFT) was originally thought to be a spe-
cific inhibitor of signaling by the tumor suppressor pro-
tein p53. However, the laboratory that discovered
pifithrin recently reported that the compound also in-
hibits heat shock and glucocorticoid receptor (GR) sig-
naling, and they suggested that PFT targets a factor
common to all three signal transduction pathways, such
as the hsp90/hsp70-based chaperone machinery
(Komarova, E. A., Neznanov, N., Komarov, P. G.,
Chernov, M. V., Wang, K., and Gudkov, A. V. (2003)
J. Biol. Chem. 278, 15465–15468). Because it is important
for the mechanistic study of this machinery to identify
unique inhibitors of chaperone action, we have exam-
ined the effect of PFT on transcriptional activation,
the hsp90 heterocomplex assembly, and hsp90-depend-
ent nuclear translocation for both p53 and the GR. At
concentrations where PFT blocks p53-mediated induc-
tion of p21/Waf-1 in human embryonic kidney cells, we
observed no inhibition of GR-mediated induction of a
chloramphenicol acetyl transferase reporter in LMCAT
cells. PFT did, however, cause a left shift in the dexa-
methasone dose response curve by increasing intracel-
lular dexamethasone concentration, apparently by com-
peting for dexamethasone efflux from the cell. The
assembly of p53 or GR heterocomplexes with hsp90 and
immunophilins was not affected by PFT either in vivo
or in vitro and did not affect the nuclear translocation of
either transcription factor. Thus, we conclude that
PFT does not inhibit GR-mediated induction or the
function of the chaperone machinery, and, as originally
thought, it may specifically inhibit p53 signaling by act-
ing at a stage after p53 translocation to the nucleus.
The tumor suppressor protein p53 is a transcription factor
that induces growth arrest or apoptosis in response to a variety
of stress signals (1–3). The p53 gene is lost or mutated in more
than half of all human tumors (4), and inactivation of p53 is the
most common alteration found in human cancer (5, 6). Activa-
tion of p53-mediated apoptosis in response to a stress, such as
DNA damage, results in the elimination of potential tumor cell
precursors. Thus, p53 is referred to as a tumor suppressor, and
p53 knock-out mice have a high incidence of spontaneous tu-
mors (7). Although p53-mediated apoptosis is important for
tumor suppression, it may contribute to side effects of therapy
such as myelosuppression (reviewed in Ref. 8).
It was with the intention of suppressing the side effects of
cancer treatment that Komarov et al. (9) screened a library of
10,000 synthetic chemicals for inhibitors of p53-dependent apo-
ptosis. A stable, water-soluble inhibitor of p53-dependent apo-
ptosis was identified that was also shown to reduce the activa-
tion of p53-regulated genes, including cyclin G, p21/Waf-1, and
mdm2 (9). The compound was named pifithrin- (PFT),1 an
abbreviation for p-fifty three inhibitor, and it was shown to
protect mice from the lethal genotoxic stress associated with
cancer treatment without promoting the formation of tumors
(9). Subsequently, PFT has been shown to protect against
doxorubicin-induced apoptosis in mouse heart (10) and camp-
tothecin-, ischemia-, and dopamine-induced apoptosis in neu-
rons (11, 12), cisplatin-induced apoptosis in cochlear and ves-
tibular hair cells (13), and endotoxin-induced apoptosis in liver
tissue (14).
The p53 protein itself or perhaps factors required for p53-
mediated transcriptional activation have been thought to be
the molecular target of PFT. However, Komarova et al. (15)
recently published a report revealing that PFT suppresses
signaling through the heat shock transcription factor HSF1
and the glucocorticoid receptor (GR) but not signaling by NF-
B. This finding indicated that PFT may not specifically tar-
get p53 but targets some unknown cellular component that is
common for three major signal transduction pathways. Inas-
much as p53, HSF1, and the GR are all bound to and regulated
by hsp90 (see Ref. 16 for review), it was suggested that heat
shock proteins of the hsp90/hsp70-based machinery are obvious
candidate targets for PFT (15).
We have recently demonstrated that p53hsp90 and
GRhsp90 complexes exist in identical large heterocomplexes
containing dynein and one of three immunophilins, namely
FKBP52, cyclophilin 40 (CyP-40), or PP5 (17). The association
of either transcription factor with hsp90 is critical both for
maintenance of its inactive state and for rapid translocation to
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the nucleus after its activation by stress or steroid (16–19).
Because it would be very useful to have additional inhibitors of
the hsp90/hsp70-based chaperone machinery, we have tested
the proposal of Komarova et al. (15) by examining PFT effects
on p53-mediated and GR-mediated transcriptional activation,
the formation of heterocomplexes with hsp90 and immunophi-
lins, and the nuclear movement of the two transcription fac-
tors. We find that, at concentrations where PFT abrogates
p53-dependent induction of p21/Waf-1, there is no inhibition of
dexamethasone-dependent activation from a GR-dependent
reporter construct. However, PFT did cause a left shift in the
dose response curve of dexamethasone, apparently by com-
peting for dexamethasone efflux from the cell. PFT did
not affect assembly of either p53hsp90immunophilin or
GRhsp90immunophilin complexes in vivo or in vitro, and it
did not affect nuclear translocation of either transcription fac-
tor. Our observations indicate that PFT may very well be a
specific inhibitor of p53 signaling that does not affect the
hsp90/hsp70-based chaperone machinery and that inhibits p53
function at a stage after its translocation to the nucleus.
EXPERIMENTAL PROCEDURES
Materials—PFT (1-(4-methylphenyl)-2-(4,5,6,7-tetrahydro-2-imino-
3(2H)benzothiazolyl)ethanone hydrobromide) was purchased from Bi-
omol Research Laboratories (Plymouth Meeting, PA). PFT and the
cyclic PFT analog were also purchased from Alexis Biochemicals (San
Diego, CA), and similar results to those seen with PFT from Biomol
were observed. Untreated rabbit reticulocyte lysate was purchased
from Green Hectares (Oregon, WI). [6,7-3H]Dexamethasone (40 Ci/
mmol), [ring-3,5-3H]chloramphenicol (38 Ci/mmol), and 125I-conjugated
goat anti-mouse and goat anti-rabbit IgGs were obtained from
PerkinElmer Life Sciences (Boston, MA). Protein A-Sepharose, doxoru-
bicin, nonradiolabeled dexamethasone, charcoal-stripped calf serum,
pristane, mixed xylenes, and goat anti-mouse and goat anti-rabbit
horseradish peroxidase-conjugated antibodies were from Sigma. Dul-
becco’s modified Eagle’s medium (DMEM) was from Bio-Whittaker
(Walkersville, MD). Rhodamine-conjugated donkey anti-mouse IgG was
from Jackson ImmunoResearch (West Grove, PA). The BuGR2 mono-
clonal IgG used to immunoblot the GR and the rabbit polyclonal anti-
body against cyclophilin 40 were from Affinity Bioreagents (Golden,
CO). The AC88 monoclonal IgG against hsp90 was from StressGen
Biotechnologies (Victoria, British Columbia, Canada). The anti-p21/
Waf-1 monoclonal antibody (Ab-1) was from Oncogene Research Prod-
ucts (San Diego, CA). The Ab421 pan-specific mouse monoclonal anti-
body used to immunoadsorb p53 was kindly provided by Dr. Michael
Clarke (University of Michigan Medical School). The Ab-4 mouse mono-
clonal IgG used for localization of p53 by indirect immunofluorescence
and the Ab-7 sheep antiserum used to immunoblot p53 were purchased
from Calbiochem. The FiGR monoclonal IgG used to immunoadsorb the
GR was generously provided by Dr. Jack Bodwell (Dartmouth Medical
School, Lebanon, NH). The UPJ56 rabbit antiserum against FKBP52
was provided by Dr. Karen Leach (Pfizer) and the rabbit antiserum
against PP5 was provided by Dr. Michael Chinkers (University of South
Alabama, Mobile, AL). Rhodamine-conjugated goat anti-mouse IgG was
from Jackson ImmunoResearch. The mouse mammary tumor virus-
chloramphenicol acetyltransferase (MMTV-CAT) reporter plasmid and
the mouse fibroblast L929 cell line stably transfected with MMTV-CAT
(LMCAT cells) were provided by Dr. Edwin Sanchez (Medical College of
FIG. 1. PFT inhibits p53-mediated transcription in HEK cells.
A, exponentially growing HEK cells were incubated with 0–100 M
PFT for 4 h in the presence or absence of 500 nM doxorubicin (Dox).
Cells were harvested, and whole cell cytosols were prepared. Hsp90,
p53, and p21/Waf-1 were resolved by electrophoresis and immunoblot-
ting. B, exponentially growing HEK cells were incubated for 1–24 h
with 500 nM doxorubicin in the presence () or absence () of 30 M
PFT. Cells were harvested, and whole cell cytosols were prepared.
Hsp90, p53, and p21 were resolved by electrophoresis and immunoblot-
ting as in panel A.
FIG. 2. PFT does not affect GR-mediated transcription from a
transiently transfected reporter in HeLa or L929 cells. A, tran-
scription in HeLa cells. HeLa cells transiently transfected with MMTV-
CAT reporter plasmid as described under “Experimental Procedures”
were treated for 2 (open bars) or 20 h (solid bars) with vehicle, 30 M
PFT, 1 M dexamethasone (Dex), or dexamethasone and PFT. The
data represent the mean  S.E. of three samples expressed as fold
induction over the vehicle-treated sample set at 1. B, transcription in L
cells. L cells transiently transfected with MMTV-CAT were treated as
described above.
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Ohio, Toledo, OH). DLD-1 human colon adenocarcinoma cells were
purchased from the American Type Culture Collection (Manassas, VA).
HT29-tsp53 (formerly referred to as ts29-G cells) human colorectal
cancer cells overexpressing a temperature-sensitive mutant of mouse
p53 were described previously (20, 21).
Cell Culture and Cytosol Preparation—Cultures of mouse fibroblast
L929 cells, L929 cells stably transfected with an MMTV-CAT reporter
plasmid (LMCAT cells), HeLa cells, human embryonic kidney (HEK)
cells, and NIH 3T3 mouse fibroblast cells, all expressing wild-type p53,
were cultured in DMEM supplemented with 10% bovine calf serum.
DLD-1 cells were cultured in DMEM supplemented with 10% fetal calf
serum, 2 mM L-glutamine, 1.5 g/liter NaHCO3, 4.5 g/liter glucose, and 1
mM pyruvate. Cells were harvested by scraping into Hanks’ buffered
saline solution and centrifugation. Cell pellets were washed in Hanks’
buffered saline solution, resuspended in 1.5 volumes of HEM buffer (10
mM NaOH-Hepes, 1 mM EDTA, and 20 mM sodium molybdate, pH 7.4)
with 1 mM phenylmethylsulfonyl fluoride and 1 tablet of Complete-Mini
protease inhibitor mixture (Roche Applied Science) per 3 ml of buffer
and ruptured by Dounce homogenization. The lysate was then centri-
fuged at 100,000  g for 30 min, and the supernatant, referred to as
“cytosol,” was collected, aliquoted, flash-frozen, and stored at 70 °C.
Mouse GR was expressed in Sf9 cells, and cytosol was prepared as
described previously (22).
Indirect Immunofluorescence of GR and p53—NIH 3T3 cells were
grown on 11  22 mm coverslips placed in 35-mm culture wells in 2 ml
of DMEM supplemented with bovine calf serum. When the cells were
50% confluent, the culture medium was replaced with phenol red-free
DMEM supplemented with 10% charcoal-stripped calf serum, and the
FIG. 3. Effect of PFT on GR-mediated transcription from a
stably transfected reporter by receptor saturating and subsatu-
rating concentrations of steroid. A, PFT does not affect transcrip-
tion at a GR saturating concentration of dexamethasone (Dex). Mouse
fibroblast cells stably transfected with the MMTV-CAT reporter plas-
mid (LMCAT cells) were incubated with 0–30 M PFT for 20 h in the
presence or absence of 1 M dexamethasone. Cells were washed in PBS
and harvested by cell scraping. Whole cell cytosols were prepared and
assayed for expression of the translated reporter gene by assaying CAT
activity. B, PFT potentiates GR-mediated transcription at subsaturat-
ing concentrations of dexamethasone. LMCAT cells were incubated
with 0–30 M PFT for 2 h in the presence of 0–100 nM dexamethasone.
Whole cell cytosols were assayed for expression of the translated re-
porter gene by assaying CAT activity.
FIG. 4. Effect of PFT on steroid binding. A, PFT does not affect
steroid binding in vitro. Cytosol from LMCAT cells was incubated
overnight on ice with radiolabeled dexamethasone (Dex) in the presence
() or absence () of 30 M PFT. Steroid binding was assayed by
charcoal assay, and specific binding activity was calculated by subtract-
ing the activity of a duplicate sample incubated with 1,000-fold excess
non-radioactive dexamethasone. B, PFT treatment increases steroid
binding to GRs in vivo. LMCAT cells were incubated for 2 h with 100 nM
[3H]dexamethasone in the presence of 0–30 M PFT and the presence
or absence of a 1,000-fold excess of non-radioactive dexamethasone.
Cytosols were prepared, and steroid binding was determined by char-
coal assay. C, PFT treatment increases [3H]dexamethasone retention
in cells. LMCAT cells were incubated for 2 h with 100 nM [3H]dexam-
ethasone in the presence of 0–30 M PFT, and the amount of radio-
activity in washed cell pellets was assayed.
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cells were grown for an additional 24 h. Cells were incubated with
0.05% Me2SO or 100 M PFT for 2 h prior to the addition of 0.1%
ethanol or 1 M dexamethasone for 10 min to permit nuclear translo-
cation of the GR. HT29-tsp53 cells were grown at 39 °C (non-permissive
temperature) on coverslips placed in 35-mm culture wells in 2 ml of
DMEM containing 10% bovine calf serum and 2 mM L-glutamine. Nu-
clear translocation of p53 was triggered by reducing the incubation
temperature of HT29-tsp53 cells from 39 to 32 °C. Cells were fixed and
permeabilized by immersion in cold (20 °C) methanol and immuno-
stained by inverting the coverslip on a 50-l solution of phosphate-
buffered saline with 1% bovine serum albumin containing 1 l of the
Ab-4 mouse monoclonal IgG against p53 or 1 l of FiGR mouse mono-
clonal IgG overnight at 4 °C in a humid chamber. The coverslips were
incubated with a washing buffer (20 mM Tris-HCl, pH 8, 630 mM NaCl,
0.05% Tween 20, and 1% bovine serum albumin) for 30 min at room
temperature, and reincubated with 1:100 dilution of rhodamine-conju-
gated donkey anti-mouse IgG counter-antibody for 2 h. Coverslips were
rinsed in washing buffer for 30 min and mounted on microscope slides
using a drop of mounting medium (1 mg/ml phenylenediamine in 10%
phosphate-buffered saline and 90% glycerol, pH 9).
Cells were observed with a Leitz Aristoplan epi-illumination micro-
scope and scored for GR or p53 translocation as described previously
(23) using a score of 4 for nuclear fluorescence much greater than
cytoplasmic fluorescence, 3 for nuclear fluorescence greater than cyto-
plasmic fluorescence, 2 for nuclear fluorescence equal to cytoplasmic
fluorescence, 1 for nuclear fluorescence less than cytoplasmic fluores-
cence, and 0 for nuclear fluorescence much less than cytoplasmic fluo-
rescence. The translocation scores represent the mean  S.E. of three
experiments in which  50 cells per condition per experiment were
counted.
Transient Transfection of MMTV-CAT Reporter—L929 or HeLa cells
were grown as monolayer cultures in 35-mm culture wells to 50%
confluency, washed, and incubated for 1 h with 1 ml of serum-free
medium containing 5 g of plasmid DNA and 15 l of TransFast
transfection reagent (Promega). The transfection medium was replaced
with regular medium, and the cells were incubated for 48 h. During the
incubation, cells were treated for 2 or 20 h with dexamethasone or PFT
or both as indicated in the legend of Fig. 2.
GR-mediated Transcriptional Activation—Dexamethasone-induced
CAT gene expression was assayed by measuring CAT enzymatic activ-
ity in HeLa, L cell, and LMCAT cell cytosol, using a modified version of
the CAT assay described in Kwok et al. (24). LMCAT cells were grown
in 35-mm culture wells to 50% confluence and incubated with varying
concentrations of dexamethasone and PFT for up to 24 h. Cells were
washed, harvested, resuspended in potassium phosphate buffer (100
mM potassium phosphate and 1 mM dithiothreitol, pH 7.8), and rup-
tured by exposing the cell suspensions to three freeze-thaw cycles. Cell
suspensions were centrifuged at 18,000  g for 10 min, and the protein
concentration of the supernatants was measured by a Bradford assay.
Aliquots of the supernatants containing 10 g of total protein were
incubated for 15 min at 70 °C in 150 mM Tris-HCl buffer, pH 7.4. The
aliquots were added to a CAT reaction mixture (50 nM purified
[3H]chloramphenicol, 150 mM Tris-HCl, pH 7.4, and 0.25 mM butyryl
CoA) and incubated for 2 h at 37 °C. An organic phase mixture consist-
ing of 2 parts pristane and 1 part mixed xylenes was added and samples
were thoroughly subjected to a vortex. The reaction mixture was cen-
trifuged at 20,000  g for 10 min, and 150 l of the organic phase was
counted by liquid scintillation spectrometry.
Immunoadsorption of GR and p53—Receptors were immunoad-
FIG. 5. PFT does not affect the composition of p53 or GR
heterocomplexes formed in cells. DLD-1 cells were incubated for
12 h with (lane 3) or without (lanes 1 and 2) 30 M PFT; cytosol was
prepared and immunoadsorbed with non-immune IgG (lane 1, IgG) or
with antibody against p53 (Ab421) or the GR (FiGR) (lanes 2 and 3). The
immunopellets were washed, and proteins were resolved by SDS-poly-
acrylamide gel electrophoresis and detected by immunoblotting for the
indicated proteins.
FIG. 6. PFT does not affect cell-free assembly of p53 or GR heterocomplexes with hsp90 and immunophilins. Replicate immunopel-
lets of p53 (A) or GR (B) were stripped of associated chaperones, and the stripped immune pellets (Str) were incubated for 20 min at 30 °C with
reticulocyte lysate (RL), an ATP-regenerating system, 20 mM molybdate, and various concentrations of PFT. Proteins in the washed immune
pellets were resolved by electrophoresis and immunoblotting. Replicate GR immune pellets were incubated with [3H]dexamethasone to determine
steroid binding activity. Lane 1 (counting from the left), stripped immune pellet; lanes 2–5, stripped pellet incubated with reticulocyte lysate and
Me2SO vehicle (lane 2) or 10 (lane 3), 30 (lane 4), or 100 M PFT (lane 5).
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sorbed from aliquots of 50 (for measuring steroid binding) or 100 l (for
Western blotting) of Sf9 cell cytosol by rotation for 2 h at 4 °C with 18
l of protein A-Sepharose precoupled to 9 l of FiGR ascites suspended
in 200 l of TEG buffer (10 mM TES, pH 7.6, 50 mM NaCl, 4 mM EDTA,
and 10% glycerol). p53 was immunoadsorbed from 250-l aliquots of
DLD-1 cytosol with 10 l of Ab421 antibody. Prior to incubation with
reticulocyte lysate, immunoadsorbed p53 and GR were stripped of as-
sociated hsp90 by incubating the immunopellet for an additional 2 h at
4 °C with 350 l of 0.5 M NaCl in TEG buffer. The pellets were then
washed once with 1 ml of TEG buffer followed by a second wash with 1
ml of Hepes buffer (10 mM Hepes, pH 7.4).
GRhsp90 and p53hsp90 Heterocomplex Reconstitution—Immu-
nopellets containing GR or p53 stripped of chaperones were incubated
with reticulocyte lysate and 5 l of an ATP-regenerating system (50
mM ATP, 250 mM creatine phosphate, 20 mM magnesium acetate, and
100 units/ml creatine phosphokinase). The assay mixtures were in-
cubated for 20 min at 30 °C with suspension of the pellets by shaking
the tubes every 2 min. At the end of the incubation, the pellets were
washed twice with 1 ml of ice-cold TEGM buffer (TEG with 20 mM
sodium molybdate) and assayed for steroid binding capacity and for
GR- or p53-associated proteins.
Assay of Steroid Binding Capacity—For measuring hormone reten-
tion in intact cells, exponentially growing LMCAT cells (2  106
cells/25 cm2 flask) were incubated with 100 nM [3H]dexamethasone at
37 °C for 2 h in the absence or presence of 1,000-fold excess unlabeled
dexamethasone and the presence of Me2SO or PFT. Cells were
washed, harvested, and suspended in cold phosphate-buffered saline
and counted by liquid scintillation spectrometry. Specific binding activ-
ity was calculated by subtracting the radioactivity in the cells incubated
in the presence of excess unlabeled dexamethasone.
Immune pellets to be assayed for steroid binding were incubated
overnight at 4 °C in 50 l of HEM buffer plus 100 nM [3H]dexametha-
sone. Samples were then washed three times with 1 ml of TEGM buffer
and counted by liquid scintillation spectrometry. The steroid binding is
expressed as counts/min of [3H]dexamethasone bound/FiGR immu-
nopellet prepared from 50 l of cytosol.
For cytosols to be assayed for steroid binding, a 50 l aliquot of
cytosol was incubated overnight at 4 °C in 50 l of HEM buffer with 100
nM [3H]dexamethasone plus or minus a 1,000-fold excess of non-radio-
active dexamethasone. Samples were mixed with dextran-coated char-
coal, centrifuged, and counted by liquid scintillation spectrometry. The
steroid binding is expressed as counts/min of bound [3H]dexametha-
sone/100 l of cell cytosol.
Gel Electrophoresis and Western Blotting—Immune pellets were re-
solved on 12% SDS-polyacrylamide gels and transferred to Immo-
bilon-P membranes. The membranes were probed with 0.1% Ab-7 for
p53, 0.25 g/ml BuGR2 for GR, 1 g/ml AC88 for hsp90, 1 g/ml
anti-p21/Waf-1, 0.1% UPJ56 for FKBP52, 0.1% anti-cyclophilin 40, or
0.1% anti-PP5. The immunoblots were then incubated a second time
with the appropriate 125I-conjugated or horseradish peroxidase-conju-
gated counterantibody to visualize the immunoreactive bands. p53 was
revealed by enhanced chemiluminescence. Because PP5, FKBP52, and
p53 migrate in the same region upon gel electrophoresis, we electro-
phoresed replicate samples of both non-immune and immune pellets
and probed replicate immunoblots with an antibody specific for each
protein. Thus, the Western blots of Figs. 5 and 6 are necessarily com-
posites prepared from two or more replicate immunoblots.
RESULTS AND DISCUSSION
PFT Effect on p53- and GR-mediated Transcription—To
confirm the activity of the PFT preparation as an inhibitor of
FIG. 7. PFT does not affect nuclear translocation of p53 or the GR. A, p53 translocation. HT29-tsp53 colon cancer cells were preincubated
for 1 h in the presence of 100 M PFT (PFT) or Me2SO vehicle (PFT), and p53 translocation to the nucleus was triggered by shifting the
temperature from 39 to 32 °C. After 1 h at 32 °C, the cells were fixed and permeabilized and immunostained for p53. B, GR translocation. NIH 3T3
mouse fibroblasts were pretreated with 100 M PFT or with Me2SO vehicle for 1 h and then incubated with (DEX) or without (DEX) 1 M
dexamethasone for 10 min to allow nuclear translocation. Cells were fixed, and GR was visualized by immunostaining. The graphs show data
compiled from  50 cells for each condition scored for nuclear translocation on a scale of 0 for completely cytoplasmic fluorescence to 4 for
completely nuclear fluorescence. Bars represent the average score  S.E. for each condition.
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p53 signaling, HEK cells were treated with doxorubicin to
cause DNA damage and activate p53. As shown in Fig. 1A,
doxorubicin treatment causes an increase in the amount of
p21/Waf-1 that is prevented by 10 M PFT. The PFT inhibi-
tion of p21/Waf-1 induction is sustained over 24 h of doxorubi-
cin treatment (Fig. 1B).
To determine the effect of PFT on GR-mediated transcrip-
tion, HeLa cells (Fig. 2A) or L929 mouse fibroblasts (Fig. 2B)
were transiently transfected with an MMTV-CAT reporter
plasmid and treated for 2 or 20 h with 1 M dexamethasone or
30 M PFT or both prior to the assay of CAT activity. In both
cell lines, there was a robust induction of CAT by dexametha-
sone that was not affected by PFT. To further test any possi-
ble effect of PFT on dexamethasone-dependent induction, we
used a subline of L929 mouse fibroblasts stably transfected
with an MMTV-CAT reporter plasmid (LMCAT cells) that was
developed by Ning and Sanchez (25). When the LMCAT cells
are treated with dexamethasone, there was an induction of
CAT driven by the endogenous L cell GR. As shown in Fig. 3A,
PFT did not inhibit GR-mediated CAT induction when cells
were treated with a high concentration (1 M) of dexametha-
sone. At lower concentrations of dexamethasone and a short
induction time, PFT stimulated dexamethasone-dependent
CAT induction (Fig. 3B).
PFT Increases the Concentration of Dexamethasone in
Cells—Potentiation of a dexamethasone response like that
shown in Fig. 3B has been reported with immunosuppressant
drugs (reviewed in Ref. 26). It is known that both dexametha-
sone and the immunosuppressant drugs, such as FK506, are
transported out of the cell by the multidrug transporter Mdr1,
and Kralli and Yamamoto (27) showed that FK506 potentiates
dexamethasone responsiveness in L cells by increasing dexam-
ethasone accumulation without altering the hormone binding
properties of the GR. Here, we show that PFT did not affect
the binding activity of the GR when it was added to cytosol (Fig.
4A), but treatment of LMCAT cells with PFT increased the
amount of [3H]dexamethasone bound to GRs in vivo (Fig. 4B).
As shown in Fig. 4C, treatment with PFT increased the
amount of [3H]dexamethasone retained in the cell. This in-
crease in intracellular dexamethasone is likely due to PFT
competition for efflux in the same manner as that seen with the
immunosuppressant drugs, and it forms the basis for a poten-
tial drug interaction.
PFT Does Not Inhibit Assembly of Heterocomplexes with
hsp90 and Immunophilins—To examine the effects of PFT on
the assembly of p53hsp90immunophilin complexes in vivo, we
selected the DLD-1 human colorectal cancer cell line, which
possesses a point mutation that converts serine 241 of p53 to
phenylalanine (28). This mutant p53 is localized in the cyto-
plasm where it exists in cytosolic heterocomplexes with hsp90
(29). We have shown previously that the p53hsp90 heterocom-
plexes contain the immunophilins that are present in GRhsp90
heterocomplexes (17). Fig. 5 is an immunoblot of hsp90 and the
tetratricopeptide repeat domain immunophilins co-immunoad-
sorbed with p53 or the GR from cytosol prepared from un-
treated DLD-1 cells (Fig. 5, lanes 2) or DLD-1 cells treated with
PFT (lanes 3). In neither case did PFT affect heterocomplex
formation in vivo.
Heterocomplexes with hsp90 and the tetratricopeptide re-
peat domain immunophilins that bind hsp90 can be assembled
in vitro by incubating immunoadsorbed p53 or GR that has
been stripped of endogenous bound chaperones with rabbit
reticulocyte lysate. Fig. 6 presents immunoblots of hsp90 and
immunophilins that associate with p53 (Fig. 6A) and the GR
(Fig. 6B) during such cell-free heterocomplex assembly. It is
clear that PFT did not affect assembly in either case. When
the GR is assembled into GRhsp90 heterocomplexes, it is con-
verted from a non-steroid binding state to a steroid binding
state, and, as shown in the bar graph in Fig. 6B, the generation
of steroid binding activity was not affected by pifithrin.
PFT Does Not Inhibit Nuclear Translocation of p53 or GR—
Both p53 and the GR utilize an hsp90-dependent movement
system for translocation to the nucleus along microtubular
tracts driven by the cytoplasmic dynein motor protein (17–19,
23, 30, and reviewed in Ref. 31). In the movement system, the
immunophilins bind via their tetratricopeptide repeat domain
to hsp90 and via their peptidylprolyl isomerase domain to the
dynamitin component of the dynein-associated dynactin com-
plex. Thus, rapid nuclear translocation of either the GR or p53
requires dynamic assembly of heterocomplexes with hsp90, and
movement is impeded by geldanamycin and radicicol, which
inhibit hsp90 heterocomplex assembly (17, 18, 23). Nuclear
translocation of p53 or the GR is also inhibited when immu-
nophilin binding to dynein is competed by expression of a
peptidylprolyl isomerase domain fragment or when dynein
linkage to cargo is dissociated by the expression of dynamitin
(17, 18, 30).
To examine the movement of p53 from the cytoplasm to the
nucleus, we chose HT29-tsp53 cells, a stable human colon car-
cinoma cell line expressing a temperature-sensitive allele of
murine p53 (20). This temperature-sensitive mutant of p53 is
fully active and nuclear at the permissive temperature of 32 °C,
but it is inactive and located in the cytoplasm at the non-
permissive temperature of 39 °C (32–34). When the incubation
temperature of HT29-tsp53 cells is shifted from 39 to 32 °C,
p53 translocates to the nucleus, with 1 h being required for
complete translocation (17). As shown in Fig. 7A, nuclear trans-
location of p53 was not affected by 100 M PFT. We routinely
examine GR translocation in 3T3 mouse fibroblasts, where the
receptor translocates to the nucleus within 10 min after the
addition of steroid (18). As shown in Fig. 7B, dexamethasone-
dependent GR translocation was not affected by 100 M PFT.
Status of Pifithrin Inhibition of Transcription—The data of
this paper differ from the observations of Komarova et al. (15)
in that we do not see PFT inhibition of GR-dependent induc-
tion. Inasmuch as we have exposed cells to much higher con-
centrations of PFT, we do not know the basis for the discrep-
ancy. The notion of Komarova et al. (15) that PFT might
inhibit the chaperone machinery that is common to p53, GR,
and HSF1 signaling (15) is intriguing and well worth testing.
Here, we do not find PFT inhibition of hsp90 heterocomplex
assembly with p53 or the GR, inhibition of functional opening
of the steroid binding cleft in the GR, or inhibition of the
nuclear transfer of either transcription factor. The absence of
PFT inhibition shows that PFT must be inhibiting some step
in the induction mechanism after p53 transfer to the nucleus.
Because, in our hands, induction by the GR is not affected, we
would suggest that PFT is not inhibiting a coactivator com-
mon to both p53-dependent and GR-dependent responses.
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